Bank Of America Corp Humacyte, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Humacyte, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 229,599 shares of HUMA stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

229,599

Previous 221,148 3.82%

Holding current value

$1.01 Million

Previous $1.06 Million 17.72%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.11 - $9.46 $43,184 - $79,946	8,451 Added 3.82%	229,599 $1.25 Million
Q2 2024 Aug 14, 2024	BUY	$2.87 - $9.1 $521,711 - $1.65 Million	181,781 Added 461.76%	221,148 $1.06 Million
Q1 2024 May 15, 2024	SELL	$2.57 - $4.84 $104,377 - $196,571	-40,614 Reduced 50.78%	39,367 $122,000
Q4 2023 Feb 14, 2024	BUY	$1.99 - $3.12 $135,069 - $211,766	67,874 Added 560.62%	79,981 $227,000
Q2 2023 Aug 14, 2023	SELL	$2.86 - $4.97 $66,386 - $115,363	-23,212 Reduced 65.72%	12,107 $34,000
Q1 2023 May 12, 2023	SELL	$2.11 - $3.25 $164,653 - $253,613	-78,035 Reduced 68.84%	35,319 $109,000
Q4 2022 Feb 10, 2023	BUY	$2.02 - $3.62 $137,212 - $245,895	67,927 Added 149.53%	113,354 $239,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $5.14 $34,451 - $145,148	-28,239 Reduced 38.33%	45,427 $148,000
Q2 2022 Aug 12, 2022	BUY	$3.21 - $7.86 $159,736 - $391,129	49,762 Added 208.17%	73,666 $236,000
Q1 2022 May 16, 2022	BUY	$4.65 - $7.4 $79,129 - $125,925	17,017 Added 247.09%	23,904 $169,000
Q4 2021 Feb 08, 2022	BUY	$7.25 - $11.6 $24,541 - $39,266	3,385 Added 96.66%	6,887 $51,000
Q3 2021 Nov 15, 2021	BUY	$9.21 - $16.99 $32,253 - $59,498	3,502 New	3,502 $40,000

Others Institutions Holding HUMA

# of Institutions

150

Shares Held

35.1M

Call Options Held

279K

Put Options Held

607K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $454M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Humacyte, Inc. Transaction History